Study of DN-101 (Calcitriol) and Docetaxel in Subjects Previously Enrolled in Studies DN101-002 or DN101-004

PHASE2UnknownINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

April 30, 2006

Study Completion Date

January 31, 2008

Conditions
Androgen Independent Prostate Cancer (AIPC)Non Small Cell Lung Cancer (NSCLC)
Interventions
DRUG

DN-101 (calcitriol) - Drug

Trial Locations (13)

10032

Columbia Presbyterian Medical Center, New York

27103

Piedmont Hematology Oncology Associates, Winston-Salem

75702

Tyler Cancer Center, Tyler

94115

Pacific Hematology Oncology Associates, San Francisco

94589

Kaiser Permanente Medical Group, Northern California, Vallejo

94704

Alta Bates Comprehensive Cancer Center, Berkeley

97227

NW Kaiser Permanente Portland, Portland

98684

Northwest Cancer Specialists Vancouver Office, Vancouver

97239-3098

Alta Bates Comprehensive Center, Portland

Oregon Health & Science University, Portland

15232-1305

University of Pittsburgh,William Copper Ambulatory Care, Pavillion Hellman Cancer Center, Pittsburgh

T2N 4N2

Tom Baker Cancer Centre, Calgary

T6G 1Z2

Cross Cancer Institute, Department of Medicine, Edmonton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novacea

INDUSTRY